Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Evolus, Inc.EOLS · Entity 5341 | Chief Financial Officer | May 13, 2025 | May 14, 2025 |
| TANDEM DIABETES CARE INCTNDM · Entity 4682 | Director | May 20, 2026 | May 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Evolus, Inc.
Report date May 13, 2025 · Filed May 14, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 167,089 |
Reported balance
After 2025-05-13 transaction · row 1
1 source rowRow 1 · 2025-05-13 · Sale · Disposed 6,494 · Balance 167,089 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of certain restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of certain restricted stock units.
TANDEM DIABETES CARE INC
Report date May 20, 2026 · Filed May 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 5,110 |
Reported balance
After 2026-05-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-20 · Grant · Acquired 5,110 · Balance 5,110 F1: Each restricted stock units (RSU) represents a contingent right to receive either one share of the Issuers common stock or cash in lieu thereof, at the Issuers discretion, in accordance with the terms of the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F2: Such RSUs were granted to the Reporting Person on May 20, 2026, and will vest on the one-year anniversary thereof, subject to the terms of the 2023 Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock units (RSU) represents a contingent right to receive either one share of the Issuers common stock or cash in lieu thereof, at the Issuers discretion, in accordance with the terms of the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).
F2: Such RSUs were granted to the Reporting Person on May 20, 2026, and will vest on the one-year anniversary thereof, subject to the terms of the 2023 Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 20, 2026 Filed May 22, 2026 20:10 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GrantRestricted Stock Unit · Derivative | 5,110 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000077 · wk-form4_1779480632.xml · derivative · entry 1 Beaver Sandra · CIK 0001944884 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,110 Underlying: Common Stock · 5,110 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock units (RSU) represents a contingent right to receive either one share of the Issuers common stock or cash in lieu thereof, at the Issuers discretion, in accordance with the terms of the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F2 · derivative.exercise_date: Such RSUs were granted to the Reporting Person on May 20, 2026, and will vest on the one-year anniversary thereof, subject to the terms of the 2023 Plan. F2 · derivative.expiration_date: Such RSUs were granted to the Reporting Person on May 20, 2026, and will vest on the one-year anniversary thereof, subject to the terms of the 2023 Plan. Read SEC document |
| November 07, 2025 Filed Nov 25, 2025 21:10 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GrantRestricted Stock Unit · Derivative | 20,242 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000221 · wk-form4_1764105030.xml · derivative · entry 1 Beaver Sandra · CIK 0001944884 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,242 Underlying: Common Stock · 20,242 shares Expires not disclosed F1 · security: Awarded on November 7, 2025 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F2 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F3 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 11/15/2026, and the remaining shares shall vest in two (2) equal annual installments thereafter. F3 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 11/15/2026, and the remaining shares shall vest in two (2) equal annual installments thereafter. Read SEC document |
| May 13, 2025 Filed May 14, 2025 23:27 UTC | Evolus, Inc. EOLS · Entity 5341 | SaleCommon Stock | 6,494 | $10.02 | $65,069.88 |
DisclosureSEC source: 0001570562-25-000080 · wk-form4_1747265253.xml · nonDerivative · entry 1 Beaver Sandra · CIK 0001944884 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 167,089 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of certain restricted stock units. Read SEC document |
| March 18, 2025 Filed Mar 20, 2025 22:27 UTC | Evolus, Inc. EOLS · Entity 5341 | SaleCommon Stock | 8,996 | $13.26 | $119,242.88 |
DisclosureSEC source: 0001570562-25-000053 · wk-form4_1742509639.xml · nonDerivative · entry 1 Beaver Sandra · CIK 0001944884 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 173,583 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of certain Restricted Stock Units. F2 · price: The shares were sold in multiple trades at prices ranging from $13.185 to $13.256. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 22:54 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantStock Option (Right to Buy) · Derivative | 50,813 | $0.00 Strike: $13.58 | $0.00 |
DisclosureSEC source: 0001570562-25-000043 · wk-form4_1741733687.xml · derivative · entry 3 Beaver Sandra · CIK 0001944884 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,813 Underlying: Common Stock · 50,813 shares Expires 2035-03-07 F4 · derivative.exercise_date: The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting annually on the anniversary of March 7, 2025, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 22:54 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantPerformance Restricted Stock Units · Derivative | 35,663 | $0.00 | $0.00 |
DisclosureSEC source: 0001570562-25-000043 · wk-form4_1741733687.xml · derivative · entry 2 Beaver Sandra · CIK 0001944884 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,663 Underlying: Common Stock · 35,663 shares Expires not disclosed F2 · derivative.exercise_price: Each performance-based restricted stock unit ("PSU") represents the right to receive, following vesting, a number of shares of common stock of the issuer up to 200% of the number of PSUs. F3 · derivative.exercise_date: The number of shares of Common Stock acquired upon vesting of the PSUs is contingent upon the achievement of a preestablished performance metrics, as approved by the Issuer's Compensation Committee, over a two-year performance period. Subject to the Issuer's compensation committee certifying the underlying performance metrics, 100% of the PSUs will vest on March 7, 2028 in each case subject to time based service requirements and continuous employment with the Issuer through the vesting dates. F3 · derivative.expiration_date: The number of shares of Common Stock acquired upon vesting of the PSUs is contingent upon the achievement of a preestablished performance metrics, as approved by the Issuer's Compensation Committee, over a two-year performance period. Subject to the Issuer's compensation committee certifying the underlying performance metrics, 100% of the PSUs will vest on March 7, 2028 in each case subject to time based service requirements and continuous employment with the Issuer through the vesting dates. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 22:54 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantCommon Stock | 35,663 | $0.00 | $0.00 |
DisclosureSEC source: 0001570562-25-000043 · wk-form4_1741733687.xml · nonDerivative · entry 1 Beaver Sandra · CIK 0001944884 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 182,579 F1 · shares: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest over a period of four years, with 1/4th of the RSU vesting annually on the anniversary of March 7, 2025, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| December 23, 2024 Filed Dec 26, 2024 22:28 UTC | Evolus, Inc. EOLS · Entity 5341 | SaleCommon Stock | 1,586 | $10.85 | $17,211.11 |
DisclosureSEC source: 0001570562-24-000139 · wk-form4_1735252093.xml · nonDerivative · entry 1 Beaver Sandra · CIK 0001944884 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 146,916 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| September 06, 2024 Filed Sep 7, 2024 01:45 UTC | Evolus, Inc. EOLS · Entity 5341 | SaleCommon Stock | 3,276 | $14.98 | $49,074.48 |
DisclosureSEC source: 0001570562-24-000121 · wk-form4_1725673547.xml · nonDerivative · entry 1 Beaver Sandra · CIK 0001944884 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,502 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| May 10, 2024 Filed May 15, 2024 00:55 UTC | Evolus, Inc. EOLS · Entity 5341 | SaleCommon Stock | 2,423 | $12.72 | $30,814.26 |
DisclosureSEC source: 0001570562-24-000084 · wk-form4_1715734540.xml · nonDerivative · entry 1 Beaver Sandra · CIK 0001944884 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 151,778 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · price: The shares were sold in multiple trades at prices ranging from $12.51 to $13.06. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 19, 2024 Filed Mar 21, 2024 22:09 UTC | Evolus, Inc. EOLS · Entity 5341 | SaleCommon Stock | 5,672 | $13.92 | $78,978.06 |
DisclosureSEC source: 0001570562-24-000054 · wk-form4_1711058949.xml · nonDerivative · entry 1 Beaver Sandra · CIK 0001944884 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 154,201 F1 · kind: The sales reported on this Form 4 were mandated by the Issuer pursuant to Restricted Stock Unit Agreements requiring the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction, and does not represent a discretionary trade by the reporting person. F2 · price: The shares were sold in multiple trades at prices ranging from $13.555 to $14.12. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 22, 2024 Filed Feb 24, 2024 01:27 UTC | Evolus, Inc. EOLS · Entity 5341 | SaleCommon Stock | 1,821 | $13.08 | $23,820.87 |
DisclosureSEC source: 0001570562-24-000029 · wk-form4_1708738037.xml · nonDerivative · entry 2 Beaver Sandra · CIK 0001944884 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 159,873 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the PSUs. Read SEC document |
| February 21, 2024 Filed Feb 24, 2024 01:27 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantCommon Stock | 13,115 | $0.00 | $0.00 |
DisclosureSEC source: 0001570562-24-000029 · wk-form4_1708738037.xml · nonDerivative · entry 1 Beaver Sandra · CIK 0001944884 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 161,694 F1 · shares: Represents shares issuable on settlement of performance restricted stock units ("PSUs") granted to the reporting person in January 2023. The Issuer's Compensation Committee certified that the reporting person had achieved the set corporate development goal as of December 20, 2023. One-third of the PSU (4,372 shares) was delivered on February 21, 2024 after certification of the milestone being achieved. The remaining two-thirds will vest annually on the anniversary of December 20, 2023 provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| February 07, 2024 Filed Feb 9, 2024 23:36 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantStock Option (Right to Buy) · Derivative | 47,337 | $0.00 Strike: $13.15 | $0.00 |
DisclosureSEC source: 0001570562-24-000018 · wk-form4_1707521768.xml · derivative · entry 3 Beaver Sandra · CIK 0001944884 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,337 Underlying: Common Stock · 47,337 shares Expires 2034-02-07 F4 · derivative.exercise_date: The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting annually on the anniversary of February 7, 2024, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| February 07, 2024 Filed Feb 9, 2024 23:36 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantPerformance Restricted Stock Units · Derivative | 17,606 | $0.00 | $0.00 |
DisclosureSEC source: 0001570562-24-000018 · wk-form4_1707521768.xml · derivative · entry 2 Beaver Sandra · CIK 0001944884 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,606 Underlying: Common Stock · 17,606 shares Expires not disclosed F2 · derivative.exercise_price: Each performance-based restricted stock unit (PSU) represents the right to receive, following vesting, a number of shares of common stock of the issuer up to 200% of the number of PSUs. F3 · derivative.exercise_date: The number of shares of Common Stock acquired upon vesting of the PSUs is contingent upon the achievement of a preestablished performance metrics, as approved by the Issuer's Compensation Committee, over a two-year performance period. Subject to the Issuer's compensation committee certifying the underlying performance metrics, 50% of the PSUs earned will vest on February 7, 2026 and the remaining 50% of the PSUs will vest on February 7, 2027, in each case subject to time based service requirements and continuous employment with the Issuer through the vesting dates. F3 · derivative.expiration_date: The number of shares of Common Stock acquired upon vesting of the PSUs is contingent upon the achievement of a preestablished performance metrics, as approved by the Issuer's Compensation Committee, over a two-year performance period. Subject to the Issuer's compensation committee certifying the underlying performance metrics, 50% of the PSUs earned will vest on February 7, 2026 and the remaining 50% of the PSUs will vest on February 7, 2027, in each case subject to time based service requirements and continuous employment with the Issuer through the vesting dates. Read SEC document |
| February 07, 2024 Filed Feb 9, 2024 23:36 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantCommon Stock | 35,211 | $0.00 | $0.00 |
DisclosureSEC source: 0001570562-24-000018 · wk-form4_1707521768.xml · nonDerivative · entry 1 Beaver Sandra · CIK 0001944884 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,579 F1 · shares: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest over a period of four years, with 1/4th of the RSU vesting annually on the anniversary of February 7, 2024, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| September 06, 2023 Filed Sep 9, 2023 00:54 UTC | Evolus, Inc. EOLS · Entity 5341 | SaleCommon Stock | 3,178 | $9.70 | $30,826.60 |
DisclosureSEC source: 0001570562-23-000106 · wk-form4_1694220838.xml · nonDerivative · entry 1 Beaver Sandra · CIK 0001944884 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 113,368 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of certain Restricted Stock Units. Read SEC document |
| August 16, 2023 Filed Aug 17, 2023 00:25 UTC | Evolus, Inc. EOLS · Entity 5341 | SaleCommon Stock | 2,211 | $10.27 | $22,706.97 |
DisclosureSEC source: 0001570562-23-000099 · wk-form4_1692231918.xml · nonDerivative · entry 2 Beaver Sandra · CIK 0001944884 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,546 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the PSUs. Read SEC document |
| August 14, 2023 Filed Aug 17, 2023 00:25 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantCommon Stock | 19,672 | $0.00 | $0.00 |
DisclosureSEC source: 0001570562-23-000099 · wk-form4_1692231918.xml · nonDerivative · entry 1 Beaver Sandra · CIK 0001944884 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,757 F1 · shares: Represents shares issuable on settlement of performance restricted stock units ("PSUs") granted to the reporting person in January 2023. On August 14, 2023, the Issuer's Compensation Committee certified that the reporting person had achieved the set corporate development goal as of May 9, 2023. One-third of the PSU (6,557 shares) was vested and delivered immediately upon certification of the goal achievement. The remaining two-thirds will vest annually on the anniversary of May 9, 2023 provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| January 25, 2023 Filed Jan 28, 2023 00:24 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantStock Option (Right to Buy) · Derivative | 85,670 | $0.00 Strike: $11.04 | $0.00 |
DisclosureSEC source: 0001570562-23-000010 · wf-form4_167486545975097.xml · derivative · entry 2 Beaver Sandra · CIK 0001944884 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,670 Underlying: Common Stock · 85,670 shares Expires 2033-01-25 F2 · derivative.exercise_date: The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting annually on the anniversary of January 25, 2023, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| January 25, 2023 Filed Jan 28, 2023 00:24 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantCommon Stock | 62,642 | $0.00 | $0.00 |
DisclosureSEC source: 0001570562-23-000010 · wf-form4_167486545975097.xml · nonDerivative · entry 1 Beaver Sandra · CIK 0001944884 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,085 F1 · shares: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest over a period of four years, with 1/4th of the RSU vesting annually on the anniversary of January 25, 2023, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| September 05, 2022 Filed Sep 6, 2022 21:08 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantStock Option (Right to Buy) · Derivative | 169,158 | $0.00 Strike: $9.06 | $0.00 |
DisclosureSEC source: 0001570562-22-000125 · wf-form4_166249851366040.xml · derivative · entry 2 Beaver Sandra · CIK 0001944884 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,158 Underlying: Common Stock · 169,158 shares Expires 2032-09-05 F2 · derivative.exercise_date: The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting annually on the anniversary of September 5, 2022, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| September 05, 2022 Filed Sep 6, 2022 21:08 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantCommon Stock | 36,443 | $0.00 | $0.00 |
DisclosureSEC source: 0001570562-22-000125 · wf-form4_166249851366040.xml · nonDerivative · entry 1 Beaver Sandra · CIK 0001944884 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,443 F1 · shares: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest over a period of four years, with 1/4th of the shares subject to the option vesting annually on the anniversary of September 5, 2022, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.